Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Generate Biomedicines, Inc. Common Stock

GENB

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Last trade $9.88
Day change -$0.61 (-5.82%)
Day range $9.76 – $10.76
Volume 586,758
Market cap $1.35B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.35B
Price / earnings
—
Price / book
3.55×
Price / sales
76.26×
EV / sales
69.39×
EV / EBITDA
-5.68×

Profitability

Earnings per share
-$1.74
Return on assets
-43.44%
Return on equity
-58.8%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.05×
Current ratio
5.01×
Quick ratio
5.01×
Cash ratio
1.7×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$248.72M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GENB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026
Revenue$4.22M$6.31M$7.22M
Cost of revenue$0$0$0
Gross profit$4.22M$6.31M$7.22M
Selling, general and administrative$13.47M$13.6M$13.52M
Research and development$82.25M$64.33M$57.81M
Total operating expenses$95.73M$77.93M$71.34M
Operating income-$91.51M-$71.61M-$64.11M
Interest expense-$192K-$155K-$182K
Income before taxes-$87.61M-$67.2M-$61.69M
Income taxes$49K$53K$28K
Net income-$87.66M-$67.26M-$61.71M
Net income attributable to common shareholders-$87.66M-$67.26M-$69.2M
EBITDA-$87.81M-$68.39M-$60.84M
Basic earnings per share-$0.68-$0.52-$1.07
Diluted earnings per share-$0.68-$0.52-$1.07

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

2027 Could Finally Be the Year Cancer Is on the Ropes!

Global cancer research is advancing through AI-supported precision medicine, biomarker-guided treatments, and innovative approaches. Anthropic is supporting pediatric cancer care through the PCX program, while companies like AstraZeneca report survival improvements in gastric cancer with sonesitatug vedotin. Researchers in Japan and South Korea are exploring novel approaches including using cancer cells' own chemistry to produce treatments and reprogramming cancer cells toward normal states.

GlobeNewswire Inc.

Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition

The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035 at a 6.15% CAGR. India's pharmaceutical market recorded 17.1% year-over-year growth in September 2026. Key growth drivers include biologics, AI-driven drug discovery, specialty medicines, and manufacturing investments. Asia Pacific is expected to grow faster than the global average at 7.02% CAGR, while North America maintains 36% market share.

The Motley Fool

Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday

Cathie Wood's Ark Invest expanded positions in three recently-IPO'd stocks on Monday: Space Exploration Technologies (SpaceX), Generate Biomedicines, and Bullish. SpaceX, trading 19% above its IPO price, joins the Nasdaq-100 on Tuesday which should drive passive buying. Generate Biomedicines, a clinical-stage biotech company with AI-driven drug discovery, is trading above its February IPO price. Bullish, a crypto exchange and media company, has plummeted 72% since going public due to crypto market weakness.

The Motley Fool

Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market

Nvidia's venture capital arm has invested $13 million in Generate Biomedicines, a biotech company developing an AI platform for virtual drug testing. The platform addresses major pharmaceutical industry challenges by reducing development time and costs, with AI-discovered drugs showing twice the success rate in phase 1 trials. This investment signals Nvidia's confidence in the company's potential to transform the $1.8 trillion pharmaceutical market.

Investing.com

A Deep Dive Into Nvidia’s Latest Portfolio Moves

Nvidia's Q1 2026 13F filing reveals strategic investments in semiconductor and cloud companies, though some announced investments don't appear due to different security structures. The company significantly increased its CoreWeave holdings to $3.657 billion (95% increase in shares), made equal $2 billion investments in both CoreWeave and Nebius, and invested in Coherent for optical networking. Nvidia also made a small $10.4 million biotech investment in Generate Biomedicines.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.